Government · 1 deal
US health agency
Every published round National Institutes of Health took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Neurizon Therapeutics Limited | Grant | 9 Sep 2026 | - | Lead | Biotech Dispatch |
Companies National Institutes of Health has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Neurizon Therapeutics Limited | Focused on revolutionising treatment of neurodegenerative diseases. | 9 Sep 2026, Grant | 1 | 1 |
Fund closes reported for National Institutes of Health, as distinct from the investments it has made.
Companies National Institutes of Health has backed that another company then bought. An exit for the holding, not a deal National Institutes of Health did.
Stories naming National Institutes of Health. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
America's NIH has agreed to fund a program giving up to 200 ALS patients access to Neurizon Therapeutics' drug NUZ-001, with Melbourne-based Neurizon as subawardee and a Boston ALS centre running it.
Vaxxas, a Brisbane biotech, has taken a worldwide licence from the US NIH to an RSV antigen candidate, aiming to advance it toward a Phase I study; another trial runs with BARDA funding.